Dissemination and Outreach Committee Chair
Department of Pharmacology
Projects 6 and 7
Beata Sperlagh is the deputy director and Head of Department of Pharmacology and Laboratory of Molecular Pharmacology of Institute of Experimental Medicine, Hungarian Academy of Sciences (IEM HAS), Budapest, Hungary; and honorary professor of Pharmacology, Semmelweis University, Budapest, Hungary.
She has graduated as an MD at the Semmelweis University, Budapest, in 1987, obtained her PhD in 1994 and DSc degree in 2004 at the Medical Section of the Hungarian Academy of Sciences, Budapest and board certificate in clinical pharmacology in 2000. She was a visiting scientist in the Center of Neurochemistry in Orangeburg, New York 1991, 1992 and 1996. Since 2016, she is the member of the Academia Europaea.
Her major scientific interest is neuroscience and pharmacology. She is a leading expert in the field of purinergic signalling in the nervous system. Her recent major achievements are the discovery of the P2X7 purinergic receptors regulating neurotransmission, identification of novel ATP release and glia-neuron cross-talk mechanisms and validation of P2X7 receptor as a new drug target in psychiatric disorders. She has also contributed with pioneering observations to the pharmacology of central cannabinoid receptors and the neurochemistry of neurodegenerative diseases. Her research team applies multidisciplinary biomedical technology to identify new drug targets in CNS disorders. She is strongly committed to the translation of basic science findings to new therapies and has established relationship with pharmaceutical companies.
Prof Sperlágh is the President of the Hungarian Society for Experimental and Clinical Pharmacology; the Section Editor of Brain Research Bulletin, Inflammopharmacology, the Associate Editor of Purinergic Signalling, The European Regional Editor of Pharmacology Research & Perspectives of BPS, Reviews Editor of Frontiers in Cellular Neuroscience and has been served as Editorial Board member of British Journal of Pharmacology, Neurochemistry International and Neurochemical Research. She is the past and present member of committees and juries of numerous national and international organizations, such as the Steering Committee of the European Academies Science Advisory Council (EASAC), European Research Council, Bioscience Advisory Board of the Hungarian Academy of Sciences, and the Hungarian National Science Foundation. She is the author of 101 peer reviewed publications in international scientific journals receiving over 4500 citations (Scopus), 6060 (google Scholar), H-index: 37/42.
Neuroscience; neuropharmacology; purinergic signalling in the nervous system; psychiatric disorders; neurodegeneration; target validation
About Institute of Experimental Medicine, Hungarian Academy of Sciences (IEM HAS)
Institute of Experimental Medicine, Hungarian Academy of Sciences (IEM HAS), Budapest, Hungary (IEM HAS, http://www.koki.hu ) in Budapest is the only research institute in Hungary dedicated exclusively to medical research. Its activity focuses on basic biomedical research, primarily in the field of neuroscience.
The research teams of the Institute employ multidisciplinary approaches on molecular, cellular and system levels with cutting-edge technologies. In general, the topics are centred around the pathomechanisms of various neurological and psychiatric disorders, as well as basic mechanisms of neurotransmission, and operational principles of various brain areas, networks and systems. The clinically related fields include epilepsy, Alzheimer’s and Parkinson’s disease, anxiety, depression, chronic stress-related disorders, malfunctions in central regulation of reproduction and energy expenditure, ischemia and neuropathic pain.
The institute is in close proximity and actively collaborates with clinics of Semmelweis University. Currently IEM HAS has 18 independent research groups, with a ~250 research staff in it. Core facilities include multiplex mRNA and protein detection systems, BD FACSVerse flow cytometer, virus laboratory, Nikon microscopy center (TIRF-2, Eclipse FN1A1R confocal live cell imaging, N-STORM super-resolution microscope), 4 electronmicroscopes, one with tomograph (FEJI), IVIS Lumina III whole animal imaging system, Behavioral Unit, Metabolic Laboratory (EchoMRI-900, metabolic profile TSE Systems), Transgenic Unit, Tissue culture lab, SPF and MD animal house.
The IEM HAS has an impressive publication record with frequent publications in premiere scientific journals (e.g. Nature, Science, Nature Neuroscience, Nature Communications, Neuron).